Sialyltransferase Inhibitors for the Treatment of Cancer Metastasis: Current Challenges and Future Perspectives

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2021 Sep 28

PMID 34577144

Citations 11

Authors

Ser John Lynon P Perez

Chih-Wei Fu

Wen-Shan Li

Affiliations

Soon will be listed here.

Abstract

Potent, cell-permeable, and subtype-selective sialyltransferase inhibitors represent an attractive family of substances that can potentially be used for the clinical treatment of cancer metastasis. These substances operate by specifically inhibiting sialyltransferase-mediated hypersialylation of cell surface glycoproteins or glycolipids, which then blocks the sialic acid recognition pathway and leads to deterioration of cell motility and invasion. A vast amount of evidence for the in vitro and in vivo effects of sialyltransferase inhibition or knockdown on tumor progression and tumor cell metastasis or colonization has been accumulated over the past decades. In this regard, this review comprehensively discusses the results of studies that have led to the recent discovery and development of sialyltransferase inhibitors, their potential biomedical applications in the treatment of cancer metastasis, and their current limitations and future opportunities.

Citing Articles

Mechanistic and Therapeutic Implications of Protein and Lipid Sialylation in Human Diseases.

Zhong X, DAntona A, Rouse J Int J Mol Sci. 2024; 25(22).

PMID: 39596031 PMC: 11594235. DOI: 10.3390/ijms252211962.

Anticancer approach by targeted activation of a global inhibitor of sialyltransferases with acrolein.

Kasahara T, Chang T, Yoshioka H, Urano S, Egawa Y, Inoue M Chem Sci. 2024; 15(25):9566-9573.

PMID: 38939146 PMC: 11206204. DOI: 10.1039/d4sc00969j.

Blockade of Sialylation with Decrease in Polysialic Acid Levels Counteracts Transforming Growth Factor β1-Induced Skin Fibroblast-to-Myofibroblast Transition.

Fioretto B, Rosa I, Tani A, Andreucci E, Romano E, Sgambati E Cells. 2024; 13(12.

PMID: 38920695 PMC: 11201575. DOI: 10.3390/cells13121067.

Development of a Novel, Potent, and Selective Sialyltransferase Inhibitor for Suppressing Cancer Metastasis.

Tsai H, Chen C, Chang T, Fu C, Chen W, Perez S Int J Mol Sci. 2024; 25(8).

PMID: 38673867 PMC: 11050067. DOI: 10.3390/ijms25084283.

The prognostic value of sialylation-related long non-coding RNAs in lung adenocarcinoma.

Wang B, Hou C, Yu X, Liu J, Wang J Sci Rep. 2024; 14(1):8879.

PMID: 38632255 PMC: 11024174. DOI: 10.1038/s41598-024-59130-3.

References

Shi M, Liu D, Duan H, Shen B, Guo N . Metastasis-related miRNAs, active players in breast cancer invasion, and metastasis. Cancer Metastasis Rev. 2010; 29(4):785-99. DOI: 10.1007/s10555-010-9265-9. View

Cui H, Wang H, Wang Y, Song J, Tian H, Xia C . ST3Gal III modulates breast cancer cell adhesion and invasion by altering the expression of invasion-related molecules. Oncol Rep. 2016; 36(6):3317-3324. DOI: 10.3892/or.2016.5180. View

Lin T, Chang W, Chen C, Tsai Y . Stachybotrydial, a potent inhibitor of fucosyltransferase and sialyltransferase. Biochem Biophys Res Commun. 2005; 331(4):953-7. DOI: 10.1016/j.bbrc.2005.03.232. View

Liu F, Patterson R, Wang J . Intracellular functions of galectins. Biochim Biophys Acta. 2002; 1572(2-3):263-73. DOI: 10.1016/s0304-4165(02)00313-6. View

Santos S, Junqueira M, Francisco G, Vilanova M, Magalhaes A, Baruffi M . O-glycan sialylation alters galectin-3 subcellular localization and decreases chemotherapy sensitivity in gastric cancer. Oncotarget. 2016; 7(50):83570-83587. PMC: 5347789. DOI: 10.18632/oncotarget.13192. View

Campo V, Sesti-Costa R, Carneiro Z, Silva J, Schenkman S, Carvalho I . Design, synthesis and the effect of 1,2,3-triazole sialylmimetic neoglycoconjugates on Trypanosoma cruzi and its cell surface trans-sialidase. Bioorg Med Chem. 2011; 20(1):145-56. DOI: 10.1016/j.bmc.2011.11.022. View

Al-Saraireh Y, Sutherland M, Springett B, Freiberger F, Morais G, Loadman P . Pharmacological inhibition of polysialyltransferase ST8SiaII modulates tumour cell migration. PLoS One. 2013; 8(8):e73366. PMC: 3739731. DOI: 10.1371/journal.pone.0073366. View

Rillahan C, Antonopoulos A, Lefort C, Sonon R, Azadi P, Ley K . Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat Chem Biol. 2012; 8(7):661-8. PMC: 3427410. DOI: 10.1038/nchembio.999. View

Chen J, Tang Y, Huang S, Juan H, Wu L, Sun Y . A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res. 2011; 71(2):473-83. DOI: 10.1158/0008-5472.CAN-10-1303. View

10.

Agard N, Bertozzi C . Chemical approaches to perturb, profile, and perceive glycans. Acc Chem Res. 2009; 42(6):788-97. PMC: 2697281. DOI: 10.1021/ar800267j. View

11.

Kolb H, Finn M, Sharpless K . Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew Chem Int Ed Engl. 2001; 40(11):2004-2021. DOI: 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5. View

12.

Tamura F, Sato Y, Hirakawa M, Yoshida M, Ono M, Osuga T . RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells. Gastric Cancer. 2014; 19(1):85-97. DOI: 10.1007/s10120-014-0454-z. View

13.

Schroder P, Giannis A . From Substrate to Transition State Analogues: The First Potent Inhibitor of Sialyltransferases. Angew Chem Int Ed Engl. 2018; 38(10):1379-1380. DOI: 10.1002/(SICI)1521-3773(19990517)38:10<1379::AID-ANIE1379>3.0.CO;2-M. View

14.

Seales E, Jurado G, Brunson B, Wakefield J, Frost A, Bellis S . Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by up-regulating cell motility. Cancer Res. 2005; 65(11):4645-52. DOI: 10.1158/0008-5472.CAN-04-3117. View

15.

Videira P, Correia M, Malagolini N, Crespo H, Ligeiro D, Calais F . ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer. 2009; 9:357. PMC: 2763879. DOI: 10.1186/1471-2407-9-357. View

16.

Perez-Garay M, Arteta B, Llop E, Cobler L, Pages L, Ortiz R . α2,3-Sialyltransferase ST3Gal IV promotes migration and metastasis in pancreatic adenocarcinoma cells and tends to be highly expressed in pancreatic adenocarcinoma tissues. Int J Biochem Cell Biol. 2013; 45(8):1748-57. DOI: 10.1016/j.biocel.2013.05.015. View

17.

Wang X, Zhang Y, Lin H, Liu Y, Tan Y, Lin J . Alpha2,3-sialyltransferase III knockdown sensitized ovarian cancer cells to cisplatin-induced apoptosis. Biochem Biophys Res Commun. 2016; 482(4):758-763. DOI: 10.1016/j.bbrc.2016.11.107. View

18.

Montgomery A, Skropeta D, Yu H . Transition state-based ST6Gal I inhibitors: Mimicking the phosphodiester linkage with a triazole or carbamate through an enthalpy-entropy compensation. Sci Rep. 2017; 7(1):14428. PMC: 5663928. DOI: 10.1038/s41598-017-14560-0. View

19.

Yuan Q, Chen X, Han Y, Lei T, Wu Q, Yu X . Modification of α2,6-sialylation mediates the invasiveness and tumorigenicity of non-small cell lung cancer cells in vitro and in vivo via Notch1/Hes1/MMPs pathway. Int J Cancer. 2018; 143(9):2319-2330. DOI: 10.1002/ijc.31737. View

20.

Li F, Ding J . Sialylation is involved in cell fate decision during development, reprogramming and cancer progression. Protein Cell. 2018; 10(8):550-565. PMC: 6626595. DOI: 10.1007/s13238-018-0597-5. View